Loss of the MTAP gene in pancreatic cancer establishes a synthetic lethal dependency on alternative metabolic pathways that can be pharmacologically inhibited.

Study: Therapeutic vulnerabilities exposed by the 9p21 loss identified through multiparametric drug screening inform rational combination strategies.

When the MTAP gene is missing in pancreatic cancer, the cancer cells become dependent on other survival pathways. Scientists found drugs that block those backup pathways, making the cancer cells die more easily — which means we can potentially treat these cancers better by targeting those weak spots.

Study: Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer

When pancreatic cancer cells lose the MTAP gene, they become dependent on another protein called PRMT5 to survive. This study shows that blocking PRMT5 along with a common cancer gene (KRAS) kills these cancer cells much better than either treatment alone.

Study: Abstract 4268: The allosteric MAT2A inhibitor IDE397 uniquely exploits metabolic liabilities associated with MTAP deletion to perturb DNA replication and repair

When pancreatic cancer cells lose the MTAP gene, they become dependent on a backup system to survive. This study shows that blocking that backup system with a drug (IDE397) kills only the cancer cells, not healthy ones — meaning we can target the weakness caused by the gene loss.